Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. / Gudbergsson, Johann Mar; Christensen, Esben; Kostrikov, Serhii; Moos, Torben; Duroux, Meg; Kjær, Andreas; Johnsen, Kasper Bendix; Andresen, Thomas Lars.

In: Molecular Neurobiology, Vol. 57, No. 9, 2020, p. 3943-3955.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Gudbergsson, JM, Christensen, E, Kostrikov, S, Moos, T, Duroux, M, Kjær, A, Johnsen, KB & Andresen, TL 2020, 'Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations', Molecular Neurobiology, vol. 57, no. 9, pp. 3943-3955. https://doi.org/10.1007/s12035-020-02004-2

APA

Gudbergsson, J. M., Christensen, E., Kostrikov, S., Moos, T., Duroux, M., Kjær, A., Johnsen, K. B., & Andresen, T. L. (2020). Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. Molecular Neurobiology, 57(9), 3943-3955. https://doi.org/10.1007/s12035-020-02004-2

Vancouver

Gudbergsson JM, Christensen E, Kostrikov S, Moos T, Duroux M, Kjær A et al. Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. Molecular Neurobiology. 2020;57(9):3943-3955. https://doi.org/10.1007/s12035-020-02004-2

Author

Gudbergsson, Johann Mar ; Christensen, Esben ; Kostrikov, Serhii ; Moos, Torben ; Duroux, Meg ; Kjær, Andreas ; Johnsen, Kasper Bendix ; Andresen, Thomas Lars. / Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. In: Molecular Neurobiology. 2020 ; Vol. 57, No. 9. pp. 3943-3955.

Bibtex

@article{c20d605d7b5543859fb5013cd2c4845c,
title = "Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations",
abstract = "Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.",
keywords = "Cancer, CD133, CD44, Glioblastoma, Plasticity, Population, Resistance, Stem cells, Subpopulation, Treatment, Tumor",
author = "Gudbergsson, {Johann Mar} and Esben Christensen and Serhii Kostrikov and Torben Moos and Meg Duroux and Andreas Kj{\ae}r and Johnsen, {Kasper Bendix} and Andresen, {Thomas Lars}",
year = "2020",
doi = "10.1007/s12035-020-02004-2",
language = "English",
volume = "57",
pages = "3943--3955",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations

AU - Gudbergsson, Johann Mar

AU - Christensen, Esben

AU - Kostrikov, Serhii

AU - Moos, Torben

AU - Duroux, Meg

AU - Kjær, Andreas

AU - Johnsen, Kasper Bendix

AU - Andresen, Thomas Lars

PY - 2020

Y1 - 2020

N2 - Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.

AB - Glioblastoma (GBM) is the most frequent and devastating primary tumor of the central nervous system with a median survival of 12 to 15 months after diagnosis. GBM is highly difficult to treat due to its delicate location, inter- and intra-tumoral heterogeneity, and high plasticity in response to treatment. In this study, we intracranially implanted primary GBM cells into mice which underwent conventional GBM treatments, including irradiation, temozolomide, and a combination. We obtained single cell suspensions through a combination of mechanical and enzymatic dissociation of brain tissue and investigated in detail the changes in GBM cells in response to conventional treatments in vivo using multi-color flow cytometry and cluster analysis. CD44 expression was elevated in all treatment groups, which was confirmed by subsequent immunohistochemistry. High CD44 expression was furthermore shown to correlate with poor prognosis of GBM and low-grade glioma (LGG) patients. Together, these results indicate a key role for CD44 in glioma pathogenesis.

KW - Cancer

KW - CD133

KW - CD44

KW - Glioblastoma

KW - Plasticity

KW - Population

KW - Resistance

KW - Stem cells

KW - Subpopulation

KW - Treatment

KW - Tumor

U2 - 10.1007/s12035-020-02004-2

DO - 10.1007/s12035-020-02004-2

M3 - Journal article

C2 - 32632605

AN - SCOPUS:85087620550

VL - 57

SP - 3943

EP - 3955

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 9

ER -

ID: 246868965